BioWorld

Dec. 22, 2004

Arena Forms Deal Worth Up To $612M With Ortho-McNeil

Arena Pharmaceuticals Inc. takes a case-by-case approach when it comes to partnering its drug candidates. If the economics are right, the San Diego-based company will sign on the dotted line. (BioWorld Today) Read More

Vicuron's NDA For Antibiotic Dalbavancin In FDA's Hands

Receptors, Signal Transduction Determine Range Of Viral Host

CAT Wins Court Battle Over Humira; Abbott Logs Appeal

Cell Therapeutics Raises $18.5M, Forms Quintiles Trisenox Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...